Role of Ayurvedic Medicine Brihatsindooradya taila in Psoriasis

Pharmaceutico-analytical and clinical study of Brihatsindooradya taila on kustha w.s.r. to Chronic Plaque Psoriasis

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/09/027611

Enrollment

Registered

2020-09-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue

Interventions

Intervention1: BRIHATSINDOORADYA TAILA: Dose : As per requirement of individual patients. Route of administration: Topical Dosage - Twice a day Treatment period: 30 days Intervention2

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with the classical features of Kustha (Chronic Plaque Psoriasis) between 18 to 70 years of age who have already undergone sansodhana. 2. Patients not taking any other medicine for Kustha (Chronic Plaque Psoriasis). 3. Patients willing to provide consent for trial.

Exclusion criteria

Exclusion criteria: 1. Pregnant women and lactating mothers. 2. Patients suffering from systemic disorders as Cardiac Problem, Uncontrolled Diabetes mellitus, Uncontrolled Hypertension, Paralysis, Malignancy, HIV, HBsAg, Leprosy. 3. Patients suffering from Psoriatic arthritis

Design outcomes

Primary

Measure	Time frame
Psoriasis Area and Severity Index ( PASI Score )Timepoint: 4 weeks	—

Secondary

Measure	Time frame
Dermatology Life Quality IndexTimepoint: 4 weeks	—

Countries

India

Contacts

Public ContactDr Sumitra Bishnoi

NATIONAL INSTITUTE OF AYURVEDA

drsanjaynia@gmail.com9887644272

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026